On March 5, 2026, Calidi Biotherapeutics, Inc. entered into an underwriting agreement for an offering of approximately 2.3 million common stock units and 9.8 million pre-funded warrant units, raising about $6.03 million before expenses, for working capital purposes. The exercise price for certain existing warrants was also reduced to $0.50 per share as part of this agreement.